Recombinant Staphylococcus aureus Phosphoenolpyruvate carboxykinase [ATP] (pckA), partial

What is the role of Phosphoenolpyruvate carboxykinase in S. aureus metabolism?

Phosphoenolpyruvate carboxykinase [ATP] (pckA) in S. aureus plays a crucial role in carbon metabolism, particularly in gluconeogenesis pathways. It catalyzes the ATP-dependent conversion of oxaloacetate to phosphoenolpyruvate and carbon dioxide, representing a rate-limiting step in the synthesis of glucose from non-carbohydrate precursors. This enzyme is particularly important when S. aureus must adapt to nutrient-limited environments where preferred carbon sources like glucose are scarce, such as within a staphylococcal abscess. The enzyme enables the bacterium to utilize alternative carbon sources, particularly amino acids that generate oxaloacetate, to sustain growth and survival under challenging nutritional conditions .

How does pckA fit into the broader amino acid catabolism network of S. aureus?

S. aureus encodes multiple pathways to catabolize amino acids, generating key metabolic intermediates including pyruvate, 2-oxoglutarate, and oxaloacetate. pckA works specifically with the oxaloacetate-generating pathways to channel these amino acid-derived carbon skeletons into gluconeogenesis. Within the metabolic network, pckA functions downstream of amino acid catabolic pathways, particularly those involving aspartate and asparagine. When S. aureus grows in environments where glucose is limiting (such as in host tissues during infection), the bacterium upregulates amino acid catabolism and the gluconeogenic pathway, including pckA, to maintain central carbon metabolism. This metabolic flexibility is critical for pathogenesis, allowing S. aureus to persist within varied host microenvironments where nutrient availability fluctuates .

What is the typical molecular structure and characteristics of recombinant pckA?

Recombinant S. aureus pckA is typically produced as a partial or full-length protein with a molecular weight of approximately 50-60 kDa, depending on the specific construct design and purification tags used. The recombinant protein generally retains the catalytic domain responsible for the ATP-dependent conversion of oxaloacetate to phosphoenolpyruvate. Similar to other recombinant S. aureus proteins, pckA is often expressed with an N-terminal or C-terminal affinity tag (commonly 6xHis-tag or SUMO-tag) to facilitate purification. The protein structure includes conserved ATP-binding and substrate-binding motifs characteristic of the phosphoenolpyruvate carboxykinase enzyme family. Recombinant preparations typically achieve >90% purity as determined by SDS-PAGE analysis and are often supplied in a stabilizing buffer containing glycerol to maintain enzymatic activity .

What expression systems are most effective for producing recombinant S. aureus pckA?

For recombinant S. aureus pckA production, E. coli-based expression systems typically yield the best results in terms of protein quantity and quality. BL21(DE3) or its derivatives are particularly suitable host strains due to their reduced protease activity and compatibility with T7 promoter-based expression vectors. For optimal expression, consider the following methodology: Transform the pckA gene (codon-optimized for E. coli) into the expression host using a vector containing an inducible promoter (T7 or tac) and an appropriate fusion tag (6xHis or SUMO). Culture cells at 37°C until mid-log phase (OD600 0.6-0.8), then induce protein expression with IPTG (0.1-1.0 mM) at a reduced temperature (16-25°C) for 16-20 hours to enhance protein solubility. This temperature reduction during induction is critical for obtaining properly folded, soluble pckA, as higher temperatures often lead to inclusion body formation. For difficult-to-express constructs, specialized E. coli strains containing additional chaperones or rare tRNAs may improve yield and solubility .

What purification strategy yields the highest purity and activity for recombinant pckA?

A multi-step purification strategy is recommended for obtaining high-purity, active recombinant pckA. Begin with immobilized metal affinity chromatography (IMAC) using Ni-NTA resin for His-tagged constructs, including stringent washing steps with 20-40 mM imidazole to remove non-specifically bound proteins, followed by elution with 250-300 mM imidazole. For SUMO-tagged constructs, after initial IMAC purification, perform on-column cleavage with SUMO protease (ULP1) to remove the tag. Follow with size exclusion chromatography using a Superdex 200 column to separate aggregates and achieve >95% purity. Throughout purification, maintain buffer conditions that stabilize the enzyme (typically 50 mM Tris-HCl pH 7.5-8.0, 150-300 mM NaCl, 5-10% glycerol, 1-5 mM DTT). To preserve enzymatic activity, avoid freeze-thaw cycles and store the purified protein in small aliquots with 50% glycerol at -80°C. Each purification batch should be validated for activity using a spectrophotometric assay measuring the conversion of oxaloacetate to phosphoenolpyruvate in the presence of ATP .

How can researchers optimize yield and solubility of recombinant pckA during expression?

Optimizing yield and solubility of recombinant pckA requires systematic adjustments to expression conditions. First, evaluate multiple construct designs: consider both full-length and truncated versions (removing flexible regions) and test different fusion partners (SUMO, MBP, or GST) that enhance solubility. Conduct small-scale expression trials varying these key parameters: induction temperature (16°C, 25°C, 30°C), IPTG concentration (0.1 mM to 1.0 mM), and induction duration (4h to overnight). Lower temperatures generally favor solubility over yield. Incorporate solubility enhancers in the growth medium: add 0.5-1% glucose to suppress leaky expression, 1-2% ethanol to induce chaperone expression, or 5-10% glycerol to stabilize folding intermediates. For recalcitrant constructs, co-expression with molecular chaperones (GroEL/ES, DnaK/DnaJ/GrpE) often dramatically improves solubility. Following expression, include mild detergents (0.05-0.1% Triton X-100) or solubilizing agents (50-300 mM arginine) in lysis buffers to prevent aggregation during cell disruption and initial purification steps .

What assays are most suitable for measuring pckA enzymatic activity?

For accurate characterization of S. aureus pckA enzymatic activity, two complementary assay types are recommended. The primary approach is a coupled spectrophotometric assay measuring the forward reaction (oxaloacetate to phosphoenolpyruvate conversion). This method couples pckA activity to pyruvate kinase and lactate dehydrogenase reactions, monitoring NADH oxidation at 340 nm as phosphoenolpyruvate is produced. The reaction mixture should contain: 50 mM HEPES (pH 7.5), 10 mM MgCl₂, 50 mM KCl, 2 mM ATP, 0.2 mM NADH, 1 mM oxaloacetate, 1 mM ADP, 2 units pyruvate kinase, and 2 units lactate dehydrogenase. For the reverse reaction, use a direct assay measuring ADP formation via coupling to pyruvate kinase and lactate dehydrogenase, with phosphoenolpyruvate, GDP, and bicarbonate as substrates. For more precise kinetic analyses, employ NMR-based assays to directly monitor substrate conversion without interference from coupling enzymes. This approach is particularly valuable when examining substrate specificity or when testing potential inhibitors that might affect coupling enzymes .

How can researchers assess the structural integrity and stability of purified recombinant pckA?

A comprehensive assessment of recombinant pckA structural integrity and stability requires multiple complementary techniques. Begin with thermal shift assays (Thermofluor/DSF) using SYPRO Orange to determine melting temperature (Tm) across different buffer conditions (varying pH 6.0-9.0, salt concentration 0-500 mM, and additives like glycerol or reducing agents). Monitor protein stability over time using dynamic light scattering (DLS) to detect early aggregation events. For higher-resolution structural analysis, employ circular dichroism (CD) spectroscopy to assess secondary structure content and confirm proper folding, comparing spectra between 190-260 nm with reference values for similar enzymes. Size exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) provides definitive determination of oligomeric state and homogeneity. For long-term stability studies, store protein aliquots at different temperatures (-80°C, -20°C, 4°C) and test activity at regular intervals (0, 1, 2, 4 weeks). Incorporate differential scanning calorimetry (DSC) for detailed thermodynamic stability parameters, particularly when comparing mutant variants or evaluating the effects of substrate binding on stability .

What experimental design best demonstrates the role of pckA in S. aureus adaptation to nutrient limitation?

To robustly demonstrate pckA's role in S. aureus adaptation to nutrient limitation, implement a multi-faceted experimental approach. First, construct a pckA deletion mutant (ΔpckA) and complemented strain using allelic exchange techniques. Compare growth kinetics of wild-type, ΔpckA, and complemented strains in complete defined medium lacking glucose but containing amino acids that generate oxaloacetate (aspartate, asparagine). Monitor growth rates, lag times, and maximum OD600 in microplate format with biological triplicates and technical duplicates. For metabolic analysis, employ ¹³C-labeled amino acids combined with NMR or mass spectrometry to track carbon flux through gluconeogenesis in wild-type versus ΔpckA strains. Validate the in vivo relevance using a murine abscess model, comparing bacterial loads and abscess characteristics between wild-type and mutant strains at 3, 5, and 7 days post-infection. Perform transcriptomic analysis (RNA-seq) comparing gene expression profiles between wild-type and ΔpckA strains during exponential and stationary phases in amino acid-rich, glucose-limited media. This comprehensive approach provides both mechanistic understanding and physiological relevance of pckA function under nutrient limitation .

How can pckA be targeted for antimicrobial development against S. aureus?

Targeting S. aureus pckA for antimicrobial development represents a promising strategy due to its critical role in bacterial adaptation to nutrient-limited environments encountered during infection. To pursue this approach, first conduct high-throughput screening of chemical libraries using the optimized spectrophotometric assay described earlier, identifying compounds that inhibit pckA activity with IC₅₀ values below 10 μM. Confirm hit specificity by counter-screening against human PEPCK to ensure selectivity. For structure-based drug design, determine the crystal structure of S. aureus pckA in complex with substrates and initial inhibitors, focusing on unique structural features distinguishing it from the human enzyme. Employ molecular dynamics simulations to identify allosteric binding sites and design allosteric inhibitors that prevent conformational changes required for catalysis. Validate promising compounds using a progression of assays: biochemical inhibition, cell-based activity against S. aureus grown in amino acid-rich, glucose-limited media (where pckA is critical), cytotoxicity assessment in human cell lines, and efficacy in murine infection models. For each inhibitor, determine whether resistance develops readily by performing serial passage experiments, characterizing any resistant mutants by whole-genome sequencing .

What is the relationship between pckA and virulence regulation in S. aureus?

The relationship between pckA and virulence regulation in S. aureus involves complex metabolic and regulatory networks. Recent research indicates that pckA activity impacts virulence through multiple mechanisms. First, conduct transcriptomic analysis comparing wild-type and ΔpckA strains grown in nutrient-limited conditions, examining differential expression of virulence genes, particularly those regulated by metabolic-sensing transcription factors. Perform chromatin immunoprecipitation sequencing (ChIP-seq) to identify transcription factors (such as CcpA) that might directly or indirectly regulate pckA expression in response to metabolic signals. Investigate the effect of pckA deletion on capsule production, biofilm formation, and expression of key virulence determinants like α-hemolysin (Hla) and protein A (Spa). Measure intracellular concentrations of key metabolic intermediates (phosphoenolpyruvate, oxaloacetate, ATP/ADP ratio) in wild-type versus ΔpckA strains and correlate these with virulence gene expression. This metabolomic analysis is crucial, as these intermediates often serve as signals for regulatory systems like CcpA that control virulence gene expression. Using in vivo infection models, compare tissue damage, bacterial dissemination, and abscess formation between wild-type and pckA-deficient strains to establish the physiological relevance of these observations .

How does pckA activity influence S. aureus antibiotic resistance profiles?

The influence of pckA activity on S. aureus antibiotic resistance profiles stems from interconnections between central metabolism and resistance mechanisms. To investigate this relationship, first determine minimum inhibitory concentrations (MICs) for clinically relevant antibiotics (oxacillin, vancomycin, daptomycin, etc.) against wild-type, ΔpckA, and complemented strains under both glucose-rich and glucose-limited conditions. Pay particular attention to β-lactam and glycopeptide resistance, as these have been linked to metabolic state in previous studies. Perform time-kill assays to assess bactericidal activity kinetics across these strains, evaluating if pckA deletion alters killing rates. For mechanistic insights, measure peptidoglycan cross-linking, cell wall thickness, and membrane potential in wild-type versus ΔpckA strains, as these parameters significantly influence antibiotic susceptibility. Conduct transcriptomic and proteomic analyses focusing on expression changes in known resistance determinants. Based on preliminary findings from the literature, pckA deletion may particularly impact methicillin resistance in MRSA strains and teicoplanin resistance in glycopeptide-intermediate S. aureus (GISA), similar to the effects observed with ccpA mutations. This connection likely involves altered carbon flux through central metabolism affecting cell wall biosynthesis pathways and stress responses critical for antibiotic resistance .

What control conditions are essential when studying pckA function in S. aureus?

When designing experiments to study pckA function in S. aureus, several critical controls must be incorporated to ensure robust and interpretable results. First, include genetic controls: wild-type parent strain, clean pckA deletion mutant (ΔpckA), and chromosomally complemented strain (ΔpckA+pckA). For plasmid-based complementation, include an empty vector control. Second, implement metabolic controls by comparing growth in media with different carbon sources: glucose-rich media (where pckA is less critical), amino acid-rich/glucose-limited media (where pckA is essential), and media supplemented with gluconeogenic substrates versus non-gluconeogenic substrates. Third, incorporate enzymatic controls when measuring pckA activity: heat-inactivated enzyme (negative control), enzyme with single substrates omitted, and reactions with known PEPCK inhibitors. For in vivo studies, compare infections in immunocompetent versus immunocompromised animals to assess how host factors interact with pckA-dependent bacterial adaptations. When analyzing transcriptional responses, include samples from multiple growth phases (early exponential, mid-exponential, early stationary) as pckA's role likely varies throughout the growth cycle. These comprehensive controls allow researchers to distinguish pckA-specific effects from general metabolic perturbations or experimental artifacts .

How should researchers design experiments to study the interplay between pckA and other metabolic enzymes in S. aureus?

To effectively study the interplay between pckA and other metabolic enzymes in S. aureus, implement a systems biology approach combining genetic, biochemical, and computational methods. Begin by constructing a panel of single and double deletion mutants targeting key enzymes in connected pathways: pckA, gudB (glutamate dehydrogenase), putA (proline utilization), mqo (malate:quinone oxidoreductase), and pyc (pyruvate carboxylase). Perform growth phenotyping of these strains across diverse nutrient conditions using Biolog phenotype microarrays to identify synthetic lethal or synthetic rescue interactions. For metabolic flux analysis, culture cells with ¹³C-labeled substrates and quantify isotopomer distributions using LC-MS/MS to map carbon flow through central metabolism in wild-type versus mutant strains. Combine these experimental data with genome-scale metabolic modeling to predict and subsequently validate flux redistributions that occur when pckA is deleted or overexpressed. For protein-protein interaction studies, employ bacterial two-hybrid assays followed by co-immunoprecipitation to identify direct interactions between pckA and other metabolic or regulatory proteins. Use CRISPRi for partial, tunable repression of target genes to assess dosage-dependent effects that complete knockouts might mask. This integrated approach reveals both direct interactions and system-level adaptations that characterize the metabolic network involving pckA .

What statistical approaches are most appropriate for analyzing pckA activity data across different growth conditions?

For robust statistical analysis of pckA activity data across different growth conditions, implement a multi-layered analytical framework tailored to biochemical and physiological experiments. Begin with proper experimental design: use randomized complete block design with at least four biological replicates and three technical replicates per condition. For enzyme kinetics data, apply non-linear regression to fit Michaelis-Menten or allosteric models using tools like GraphPad Prism or R package 'drc', comparing fitting parameters (Km, Vmax, Hill coefficients) using extra sum-of-squares F-test. For growth studies comparing multiple strains across different media conditions, employ two-way ANOVA with Tukey's post-hoc test, after confirming normality (Shapiro-Wilk test) and equal variance (Levene's test) assumptions. If these assumptions are violated, use non-parametric alternatives like Kruskal-Wallis with Dunn's post-hoc test. For time-course experiments measuring pckA activity or expression under changing conditions, apply repeated measures ANOVA or mixed-effects models that account for temporal autocorrelation. When integrating multi-omics data (transcriptomics, metabolomics, proteomics), utilize partial least squares discriminant analysis (PLS-DA) or weighted gene co-expression network analysis (WGCNA) to identify coordinated changes across datasets. Calculate effect sizes (Cohen's d or Hedge's g) in addition to p-values to quantify the magnitude of differences between conditions, particularly important when working with small sample sizes common in biochemical research .

What are the common pitfalls in recombinant pckA preparation and how can they be addressed?

Researchers commonly encounter several challenges when preparing recombinant S. aureus pckA. First, protein insolubility often occurs due to improper folding. Address this by: (1) lowering induction temperature to 16-18°C; (2) reducing IPTG concentration to 0.1-0.2 mM; (3) testing solubility-enhancing fusion partners (SUMO, MBP) instead of simple His-tags; and (4) adding solubilizing agents like 0.1% Triton X-100 or 50-300 mM arginine to lysis buffers. Second, proteolytic degradation during purification manifests as multiple bands on SDS-PAGE. Mitigate this by: (1) adding protease inhibitor cocktail to all buffers; (2) maintaining samples at 4°C throughout purification; (3) including 1-5 mM EDTA in buffers after IMAC purification; and (4) reducing purification time by optimizing protocols. Third, loss of enzymatic activity often occurs due to metal ion depletion or oxidation. Prevent this by: (1) supplementing buffers with 1-5 mM MgCl₂; (2) adding reducing agents (2-5 mM DTT or TCEP); (3) including 10-20% glycerol in storage buffers; and (4) avoiding freeze-thaw cycles by preparing single-use aliquots. Fourth, aggregation during concentration can be addressed by: (1) keeping protein concentration below 2 mg/mL; (2) adding 50-100 mM arginine to stabilize concentrated protein; and (3) using gentle concentration methods like dialysis against PEG rather than centrifugal concentrators .

How can researchers troubleshoot unexpected results in pckA functional assays?

When encountering unexpected results in pckA functional assays, follow this systematic troubleshooting approach. For unexpectedly low activity, verify enzyme integrity by SDS-PAGE and thermal shift assay to rule out degradation or misfolding. Check buffer components carefully—pckA requires specific metal cofactors (typically Mg²⁺), and metal chelators like EDTA in buffers will inhibit activity. Ensure substrate quality by preparing fresh oxaloacetate solutions immediately before use, as this substrate spontaneously decarboxylates. For coupling enzyme-based assays showing inconsistent results, prepare control reactions testing each coupling enzyme individually to verify their activity. When observing non-Michaelis-Menten kinetics, consider substrate inhibition effects or potential allosteric regulation—perform assays across wider substrate concentration ranges and test various buffer conditions (pH 6.5-8.5, salt 50-300 mM). For conflicting results between different assay methods, remember that direct and coupled assays may reflect different aspects of enzyme function; direct NMR-based approaches provide definitive measurement of actual catalysis. If activity varies between protein preparations, standardize expression and purification protocols rigorously, particularly induction time/temperature and buffer composition. For unexpected inhibitor effects, test for promiscuous inhibition mechanisms by including 0.01% Triton X-100 or 0.1 mg/mL BSA in assays to prevent non-specific aggregation-based inhibition .

What strategies can address contradictory findings when comparing in vitro pckA activity with in vivo phenotypes?

Resolving contradictions between in vitro pckA activity measurements and in vivo S. aureus phenotypes requires a multi-faceted approach addressing the complexity gap between simplified biochemical systems and biological contexts. First, reassess whether experimental conditions accurately reflect the in vivo environment by adjusting in vitro assay conditions to match physiological parameters: intracellular pH (often lower than standard buffer pH), relevant ion concentrations (particularly Mg²⁺ and K⁺), actual substrate concentrations determined by metabolomics, and the presence of metabolic intermediates that might allosterically regulate pckA. Second, investigate potential post-translational modifications of pckA in vivo using phosphoproteomics or other PTM-specific analyses, as these modifications often regulate enzyme activity but are absent in recombinant preparations. Third, examine if pckA functions within a protein complex in vivo by performing pull-down experiments followed by mass spectrometry to identify interacting partners that may modulate activity. Fourth, consider genetic compensation mechanisms by performing transcriptomics on pckA mutants to identify upregulated alternative pathways. Fifth, use metabolic flux analysis with isotope-labeled precursors to trace actual carbon flow through the gluconeogenic pathway in wild-type versus pckA mutant strains. For particularly contradictory observations, perform complementation with point mutants that maintain protein structure but lack catalytic activity to distinguish between enzymatic and potential moonlighting functions of pckA .